Preclinical dosage parameters

The short version

There is no approved human dose for BPC-157. Everything on this page comes from published animal studies, and translating those numbers to people is not straightforward.

In rodent models, effective doses have ranged from 10 ng/kg (nanogram-per-kilogram — an extremely small amount) up to 20 μg/kg (microgram-per-kilogram), with several studies finding that the nano- and micro-dose ends of that range produced similar results. That unusual U-shaped or plateau dose-response is one of the more puzzling features of the compound.

BPC-157 clears the bloodstream quickly — the plasma half-life in animal studies is under 30 minutes by intravenous injection. Eight routes of administration appear across the literature: intraperitoneal, oral, intramuscular, intravenous, topical, intra-articular, intravesicular, and subcutaneous. All dosing information here is reported from studies for context only.

Research-context dosage: what the preclinical studies used

BPC-157 research does not operate at a single dose. The preclinical literature spans orders of magnitude — from nanogram-per-kilogram to microgram-per-kilogram ranges — and the same study will sometimes show equivalent efficacy at both extremes. Understanding why requires understanding the compound's pharmacokinetics.

In musculoskeletal models, the most commonly reported intraperitoneal dose in rat studies is 10 μg/kg. This dose appears in the Achilles detachment study ^[1], the myotendinous junction study ^[6], the spinal cord compression studies ^[10][11], and the cardiac studies ^[12]. It is the reference dose for the Zagreb group's rat model work.

At the low end, 10 ng/kg intraperitoneal — three orders of magnitude lower than 10 μg/kg — has produced equivalent outcomes in several of the same models. The myotendinous junction study found 10 ng/kg and 10 μg/kg both produced full functional recovery ^[6]. The spinal cord studies used 10 ng/kg and 10 μg/kg with consistent results across assessment points ^[10]. This nano-dose efficacy is one of the more unusual pharmacological features of BPC-157 and remains an open mechanistic question.

In gastric ulcer models, BPC-157 was studied at 400–800 ng/kg intramuscular — a range that sits between the nano and micro extremes and that produced 45–65% ulcer inhibition across three models ^[8]. For oral administration in drinking water, concentrations of 0.16 μg/mL (equivalent dose) or 0.16 ng/mL were used in myotendinous junction and other models and showed activity comparable to the intraperitoneal route ^[6].

In the ischemia-reperfusion protection study, 20 μg/kg intraperitoneal was the study dose — at the higher end of the range, reflecting the acute systemic injury model context ^[14].

None of these doses have been translated into established human dose ranges. No human pharmacokinetic-pharmacodynamic model exists for BPC-157. Any extrapolation from rodent doses to human doses must account for profound pharmacokinetic differences between species.

Pharmacokinetics: half-life, bioavailability, and routes

The most complete pharmacokinetic (PK) characterization of BPC-157 was published in 2022 by He and colleagues in Frontiers in Pharmacology, using rats and beagle dogs as PK models ^[20].

Plasma half-life is very short. In rats given BPC-157 by intravenous administration, the plasma elimination half-life (t1/2) was 15.2 minutes. In beagle dogs, the IV t1/2 was 5.27 minutes — the fastest pharmacokinetic clearance in the published BPC-157 record. At four hours post-administration, BPC-157 was undetectable in plasma of either species ^[20].

Bioavailability by route varies substantially by species. After intramuscular injection:

• Rats: 14–19% bioavailability relative to IV
• Dogs: 45–51% bioavailability relative to IV

The compound is metabolized primarily to small peptide fragments and free amino acids — rapid hydrolysis of amide bonds that produces the nine urinary metabolites characterized in the 2023 anti-doping study by Tian and colleagues ^[19]. Peak tissue concentrations after IV or IM administration were found in the kidney and liver, consistent with the route of metabolic clearance ^[20].

Oral bioavailability is a more complex question. The formal PK studies do not characterize oral bioavailability with standard Cmax/AUC parameters — likely because the compound's very short systemic half-life makes traditional oral PK measurement difficult. What the research does show is that oral administration in drinking water produces measurable biological effects in rodent models — effects comparable to intraperitoneal administration in some studies ^[4][6]. The mechanistic hypothesis is that BPC-157's unusual stability in gastric juice (>24 hours) allows local GI receptor activation and paracrine signaling to drive systemic effects without requiring substantial systemic absorption ^[20].

Subcutaneous administration has been studied but is less characterized than IP, IM, and IV routes. Intra-articular and intravesicular administration appear only in the three published human pilot studies.

Routes of administration studied

Eight routes of administration appear across the BPC-157 preclinical and clinical literature:

Intraperitoneal (IP) — the dominant route in rat models. Used in musculoskeletal, neural, gastric, and cardiac studies. Not a clinically translatable route in humans (IP administration requires a needle into the peritoneal cavity under sterile technique and is used clinically only in very specific contexts such as peritoneal dialysis and intraperitoneal chemotherapy).

Oral gavage — direct intragastric delivery using a feeding needle. Used in multiple models and showed activity in the myotendinous junction study at 10 ng/kg ^[6]. Routes involving drinking water concentrate (0.16 μg/mL or 0.16 ng/mL) are sometimes categorized separately as 'oral in drinking water' and produced equivalent outcomes to IP in ligament ^[4] and MTJ ^[6] models.

Intramuscular (IM) — used in gastric ulcer models at 400–800 ng/kg and superior to intragastric at equivalent doses in that model ^[8]. The He et al. PK study characterized IM bioavailability formally as 14–19% in rats and 45–51% in dogs ^[20].

Intravenous (IV) — used in the 2022 PK study ^[20] and in one of the three human pilot studies (a two-subject IV safety study at up to 20 mg IV without adverse events) ^[16].

Topical (cream or bath application) — used in the MCL healing study at nanogram-to-microgram per kg concentrations and showed activity equivalent to IP and oral routes ^[4]. A bath application (1 mL applied directly to an ischemic colon segment) was used in the colonic ischemia study at 10 μg/kg ^[7].

Subcutaneous (SC) — studied but less pharmacokinetically characterized than IP or IM in the published literature.

Intra-articular — used in one human pilot study (knee pain, 14/16 patients with significant relief) ^[16].

Intravesicular — used in the 2024 IC pilot study (12/12 patients, 80–100% resolution at 6 weeks) ^[18].

Route equivalence across three different administration paths — IP, oral, and topical cream — was explicitly demonstrated in the MCL study ^[4]. This route flexibility is consistent with the local-receptor-activation hypothesis for oral activity and with the compound's angiogenesis-driving mechanism, which may not require systemic tissue-concentration peaks to initiate a cascade of downstream vascular signaling.

Physical form, purity, and storage in research contexts

Research-grade BPC-157 is supplied as a lyophilized (freeze-dried) powder — typically as the acetate salt, though the free base form also exists and is the subject of separate FDA review. The standard purity specification for research-grade material is ≥98% by reverse-phase HPLC (RP-HPLC) with ESI-MS confirmation of molecular weight.

The 2025 ischemia-reperfusion study sourced BPC-157 from Sigma-Aldrich at >95% purity — slightly below the common research-grade spec but a commercially sourced material with documented provenance ^[14]. The 2023 anti-doping metabolite study used stable isotope-labeled (13C/15N) BPC-157 for metabolite characterization, achieving detection limits of 0.01–0.11 ng/mL in urine with >90% recovery rates ^[19].

Physical stability follows a clear profile:

• Lyophilized powder at −20°C: stable for 2+ years
• Reconstituted solution at 4°C: use within 1–2 weeks
• Room temperature: degrades; not recommended for reconstituted solution
• In human gastric juice: stable for >24 hours — a distinctive property for a peptide ^[20]

The gastric stability is the basis for oral activity in preclinical models and distinguishes BPC-157 from most peptides, which would be rapidly cleaved by gastric proteases and would require parenteral administration to achieve systemic effects. BPC-157's proline-rich sequence (four consecutive prolines in GEPPPGKPADDAGLV) contributes to this protease resistance ^[21].